Ipamorelin and sermorelin both influence growth-hormone signaling but do so through different receptors and should not be treated as interchangeable therapies. This guide compares their mechanisms, evidence and safety considerations while separating online marketing claims from established medical evidence.
Ipamorelin is a growth hormone secretagogue that acts through the ghrelin/growth-hormone secretagogue receptor pathway. It is not an FDA-approved drug. FDA has identified concerns about compounded ipamorelin, including limited safety information, potential immunogenicity and peptide-related impurities.
Sermorelin is an analogue of growth-hormone-releasing hormone and stimulates the pituitary through the GHRH receptor. Historical approved products had specific pediatric uses; that history does not make current sermorelin products FDA approved for adult wellness, anti-aging or body composition.
Two substances can influence the same hormone system while having different pharmacology, evidence and risks. Decisions should not be based on social-media claims or a desire to maximize growth hormone. Evaluation should consider symptoms, diagnosis, medications, glucose metabolism, relevant laboratory findings and whether an FDA-approved treatment is available for the actual condition being treated.
Continue with CJC-1295 & Ipamorelin Los Angeles, Sermorelin Therapy Los Angeles, CJC-1295 vs Sermorelin, and our peptide safety guide.
No. Ipamorelin is not an FDA-approved drug.
No. Ipamorelin primarily acts through the growth-hormone secretagogue/ghrelin receptor, whereas sermorelin acts through the growth-hormone-releasing hormone receptor.
Neither should be presented as an established first-line obesity treatment. Patients seeking weight management should be evaluated for evidence-based options, including FDA-approved therapies when medically appropriate.
Written and medically reviewed by David Nazarian, MD — Board Certified in Internal Medicine. Educational information only.
